NEURONASCENT
Neuronascent discovers and develops first-in-class, small-molecule therapeutics, based on the science of neurogenesis, that target depression, neurodegenerative diseases, including Alzheimer's and Parkinson's, and Down syndrome. The Company is headquartered in Clarksville, MD and has facilities in Rockville and Walkersville, MD.
NEURONASCENT
Social Links:
Industry:
Biotechnology Life Science Medical Therapeutics
Founded:
2004-01-01
Address:
Clarksville, Maryland, United States
Country:
United States
Website Url:
http://www.neuronascent.com
Total Employee:
1+
Status:
Active
Contact:
4105316843
Email Addresses:
[email protected]
Total Funding:
1.25 M USD
Technology used in webpage:
SPF Unified Layer BlueHost
Similar Organizations
STATegics
STATegics discovers and develops allosteric small molecule modulators and cytokine receptor for the treatment of neurodegenerative diseases.
Current Employees Featured
Founder
Investors List
Maryland Department of Business and Economic Development
Maryland Department of Business and Economic Development investment in Grant - NeuroNascent
Official Site Inspections
http://www.neuronascent.com Semrush global rank: 4.85 M Semrush visits lastest month: 1.83 K
- Host name: box5778.bluehost.com
- IP address: 162.241.253.84
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "NeuroNascent"
Home - Neuronascent, Inc.
© 2024 NeuroNascent, Inc. - All Rights Reserved - Website by Teramark This website contains forward-looking statements, which are made pursuant to the safe harbor ...See details»
NeuroNascent - Crunchbase Company Profile & Funding
Neuronascent discovers and develops first-in-class, small-molecule therapeutics, based on the science of neurogenesis, that target depression, neurodegenerative diseases, including …See details»
About Us - Neuronascent, Inc.
© 2024 NeuroNascent, Inc. - All Rights Reserved - Website by Teramark. Home; About Us Founder’s Message; Management Team; Directors and AdvisorsSee details»
NeuroNascent Company Profile 2024: Valuation, Funding
Developer of a neuron regeneration therapeutics intended to offer treatment for reversing neurological disorders.See details»
Neuronascent, Inc - LinkedIn
Neuronascent (NNI) is a small corporation, that we believe has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that...See details»
Alzheimer's Disease - Neuronascent, Inc.
Neuronascent has discovered a novel class of therapeutics, called Neuron Regenerative Therapies, that aim to reverse the cognitive deficit in AD patients, by stimulating new neurons to maturation and protecting these “nascent” …See details»
NeuroNascent Company Profile - Office Locations, Competitors
NeuroNascent is a company that focuses on generating new neurons reversing neurological disorders. It discovers oral therapies supporting neuron regeneration in order to reverse …See details»
Judith Kelleher-Andersson, Ph.D. - Neuronascent, Inc. - LinkedIn
As founder and President of Neuronascent, I have discovered and am now developing a… · Experience: Neuronascent, Inc. · Location: San Francisco Bay Area · 500+ connections on …See details»
Neuronascent lands NIA grant to advance Alzheimer’s …
Aug 24, 2023 · Neuron regeneration company Neuronascent has been granted a U01 award by the National Institute of Aging (NIA) to advance its investigational drug, NNI-362, into Phase 2 clinical trials for mild to moderate Alzheimer’s …See details»
Neuronascent Receives FDA Orphan Drug Designation for NNI …
ROCKVILLE, Md., June 01, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc, today announced that the U.S. Food and Drug Administration (FDA) granted “Orphan Drug Designation” for the …See details»
Management Team - Neuronascent, Inc.
Dr. Kelleher-Andersson has over twenty years of experience developing small-molecule, central nervous system therapeutics in the biotechnology industry. Prior to founding Neuronascent, she was Director of Drug Development and …See details»
Neuronascent Announces NIA Grant Award for NNI-362 to Reach
Aug 22, 2023 · Neuronascent discovered experimental therapeutic NNI-362 through a novel screening program aimed at identifying small molecules that should enter the human brain and …See details»
NeuroNascent - Overview, News & Similar companies - ZoomInfo
Apr 11, 2023 · View NeuroNascent (www.neuronascent.com) location in Maryland, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Neuronascent Releases Further Positive Results of NNI-362 in A ...
Mar 30, 2022 · Neuronascent aims to develop NNI-362 as the first potential non-invasive, oral, neuron regenerating therapy to halt or reverse Alzheimer’s and other age-related diseases …See details»
Directors and Advisors - Neuronascent, Inc.
Directors Judith Kelleher-Andersson, Ph.D. – Read Bio Kathleen L. Mattis, MBA – Read Bio Robin Oegerle, MFA – Read Bio Maurice Gagnon – Read Bio Kenneth Narducy, Ph.D., MBA – Read …See details»
Neuronascent plans Phase II Parkinson’s disease trial with ...
Apr 19, 2023 · Neuronascent plans Phase II Parkinson’s disease trial with neurorestorative drug. The company will likely start a Phase II study in H1 2024 and raise up to $25 million in an …See details»
Reversing neurodegeneration with new neurons and clinical trials
Mar 10, 2021 · NeuroNascent seeks $20m in funding to support clinical trials of neuron regenerative therapies. Earlier this year, US biotech firm NeuroNascent published the peer …See details»
Founder's Message - Neuronascent, Inc.
Neuronascent is a small corporation, that we believe now has an over-sized opportunity to improve the well-being of millions of patients already suffering from chronic neurodegenerative …See details»
Neuronascent Releases Positive Topline Phase 1a Safety Results of …
Sep 29, 2021 · Neuronascent, Inc., [www.neuronascent.com] a privately-held, clinical-stage pharmaceutical company, was founded to discover and develop novel therapies that treat CNS …See details»
News & Events - Neuronascent, Inc.
AUG – Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease MORE. AUG – Longevity Technology News …See details»